NAD+ Injections vs IV vs Oral: Which Route Has the Evidence?

The one-sentence version

Oral NR and NMN have the most developed human trial evidence, but no route has established a human longevity benefit. A systematic review published in 2026 found no eligible intravenous or intramuscular NAD+ outcomes trial for anti-aging or wellness in its January 2010–October 2025 search¹. That is a dated finding with defined eligibility criteria, not proof that nobody has ever studied those routes.

What is actually being compared?

Why the routes are not interchangeable

Delivery into a vein, under the skin, into muscle or through the digestive tract changes exposure. It does not by itself show how much intact NAD+ reaches each tissue, or whether symptoms, function or survival improve. Oral precursors also undergo metabolism; the simple claim that one route gets NAD+ directly into every cell is not established by these studies.

For a useful comparison, ask for the same clinical outcome, in a comparable population, at a specified dose and duration. A rise in blood NAD+ and a longer life are different endpoints.

What the oral trials found

They can raise measured NAD+. One NR trial found higher NAD+ and good short-term tolerability in healthy middle-aged and older adults². That does not establish a clinical benefit.

Clinical results are mixed. A 2025 review did not support NMN or NR for preserving muscle mass and function in older adults overall³. The NICE trial did report a walking benefit with NR in peripheral artery disease: 17.6 meters versus placebo after six months. Its prespecified one-sided significance threshold was 0.10; a larger trial is needed⁴.

A few positive signals exist, in specific populations. NMN increased muscle insulin sensitivity in prediabetic women⁵, and improved aerobic capacity in amateur runners⁶. Both are real results and neither is an aging outcome.

The overall verdict. Biomarker changes have not established general anti-aging effectiveness¹.

That is the strongest evidence any NAD+ route has.

What injected, IV and nasal have

The review's IV/IM finding does not cover every product or prove universal ineffectiveness. It distinguishes clinical outcomes from an IV NAD+ pharmacokinetic pilot and an IV NMN study focused mainly on short-term safety and biomarkers¹. Neither is evidence that an at-home NAD+ injection extends life.

Subcutaneous and nasal claims need their own route-specific evidence. Do not treat the absence of eligible IV/IM trials as a systematic finding about every other route. Nor should a higher price or medical setting be treated as proof of better results.

If you have already settled on a route, the single-route guides go deeper: NAD+ injections: benefits, side effects, dosage and cost for the at-home shot, and is NAD+ IV therapy safe? for the clinic drip, including what the July 2026 Bronx case does and does not show.

What each route costs

Prices across the providers we grade are published in shapes that resist comparison — a monthly rate, a block for an estimated multi-week supply, or nothing at all until you have completed an intake. The per-provider figures, with the term each one is really sold on, are on the graded ranking and in the price table in NAD+ injections: benefits, side effects, dosage and cost, and the traps to read for are in what longevity care actually costs.

Four billing details worth checking before you compare anything:

• •Supply duration: a vial or multi-week block is not automatically a month's supply. See the plan-duration questions in our Peter MD review.
• •Commitment: check which term earns a starting price and what you pay up front; our RNK Health review separates those questions.
• •Renewal interval: four weeks is 28 days, not a calendar month. Our Luvo Health review covers recurring-plan terms.
• •Additional fees: ask whether membership, labs, shipping, consultation or administration are additional. Our Eden review explains why membership matters, while our Bioverse review identifies plan questions to resolve before checkout.

For a neutral comparison, calculate total recurring charges over the same period. A hypothetical $200 charge every four weeks totals $2,600 over 13 four-week periods; $200 per calendar month totals $2,400 over 12 months. Keep any first-order discount separate, and compare the actual dose and supply too.

How to choose, honestly

• •If you want the most developed human evidence, start with oral NR or NMN studies and their limitations. Which of the two to pick is NMN vs NR.
• •If you are considering injection or IV, ask a clinician about route-specific risks, the formulation, monitoring and the evidence for your goal.
• •If a provider says injection is proven superior, ask for the actual comparative trial and its clinical endpoint; the studies cited here do not establish that superiority.

Our broader tour of what this molecule can and cannot do is in NAD+ for longevity, and the wider toolkit is in longevity medicine: what's proven versus hyped.